| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GSK3B |
| Uniprot No | P49841 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-420aa |
| 氨基酸序列 | MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST |
| 预测分子量 | 47.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GSK3β重组蛋白的3篇示例参考文献(注：文献为虚构示例，仅用于参考格式和内容概括)：
1. **文献名称**：*"High-yield expression and purification of recombinant human GSK3β in baculovirus-insect cell system for kinase activity assays"*
**作者**：Smith J, et al.
**摘要**：本研究利用杆状病毒-昆虫细胞系统高效表达人源GSK3β重组蛋白，并通过亲和层析和离子交换层析获得高纯度蛋白。实验验证了重组蛋白的激酶活性，并优化了体外磷酸化检测条件，为药物筛选提供了可靠工具。
2. **文献名称**：*"Crystal structure of recombinant GSK3β in complex with ATP-competitive inhibitor reveals binding mechanisms"*
**作者**：Lee C, et al.
**摘要**：通过X射线晶体学解析了重组人源GSK3β蛋白与ATP竞争性抑制剂的复合物结构，揭示了抑制剂结合口袋的关键氨基酸残基，为基于结构的药物设计提供了分子基础。
3. **文献名称**：*"Functional analysis of phosphorylation sites on recombinant GSK3β using mass spectrometry and mutagenesis"*
**作者**：Garcia R, et al.
**摘要**：本研究在大肠杆菌中表达并纯化重组GSK3β，通过质谱鉴定其磷酸化修饰位点，并利用点突变技术验证特定磷酸化位点对蛋白激酶活性及底物选择性的调控作用。
4. **文献名称**：*"Development of a luminescent kinase assay platform using recombinant GSK3β for high-throughput inhibitor screening"*
**作者**：Wang Y, et al.
**摘要**：建立了一种基于重组GSK3β蛋白的发光激酶活性检测平台，优化了反应条件并验证了其灵敏度和特异性，成功应用于大规模小分子抑制剂库的筛选。
(注：如需真实文献，建议在PubMed或Google Scholar检索关键词：*recombinant GSK3β expression/purification/activity assay*)
**Background of GSK3β Recombinant Protein**
Glycogen synthase kinase-3 beta (GSK3β) is a ubiquitously expressed serine/threonine kinase involved in multiple cellular processes, including metabolism, cell proliferation, differentiation, and apoptosis. Initially identified for its role in glycogen metabolism regulation, GSK3β is now recognized as a key player in signaling pathways such as Wnt/β-catenin, PI3K/Akt, and insulin signaling. Unlike most kinases, GSK3β is constitutively active under basal conditions and is primarily regulated through inhibitory phosphorylation at Serine 9 (Ser9) by upstream signals like insulin. Dysregulation of GSK3β activity has been implicated in numerous diseases, including Alzheimer’s disease, diabetes, cancer, and mood disorders, making it a critical therapeutic target.
Recombinant GSK3β protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce high-purity, functional kinase for research and drug discovery. The recombinant form retains catalytic activity and post-translational modification sites, enabling studies on its regulation, substrate interactions, and response to inhibitors. Tagged versions (e.g., His, GST, or FLAG tags) facilitate purification, detection, and protein-protein interaction assays.
Researchers utilize GSK3β recombinant protein to investigate its role in disease mechanisms, screen small-molecule inhibitors, and validate structural models. Its application spans in vitro kinase assays, cell-based studies, and high-throughput screening platforms. Additionally, engineered mutants (e.g., constitutively active or kinase-dead variants) help dissect functional domains and phosphorylation-dependent signaling crosstalk. As GSK3β inhibitors advance in clinical trials for neurodegenerative and oncological diseases, recombinant GSK3β remains indispensable for mechanistic studies and therapeutic development.
×
